How Potential FDA Approval of Pfizer's COVID Vaccine Matters to Investors

Pfizer (NYSE: PFE) and its partner BioNTech (NASDAQ: BNTX) recently announced that they plan to soon file for full U.S. Food and Drug Administration (FDA) approval for their COVID-19 vaccine. The vaccine currently has Emergency Use Authorization. In this Motley Fool Live video recorded on May 5, Motley Fool contributors Keith Speights and Brian Orelli discuss how the potential FDA approval could matter for investors.